Predictors of long-term disease-free survival with stereotactic body radiotherapy for metachronous oligometastatic prostate cancer

doi:10.1016/j.ijrobp.2025.11.036

Predictors of long-term disease-free survival with stereotactic body radiotherapy for metachronous oligometastatic prostate cancer

2025-11-29

0

PRE

AI

DOI：10.1016/j.ijrobp.2025.11.036

Original

Original request for help

Save

Abstract

En 中文

: SBRT is increasingly used for oligometastatic prostate cancer, though most published series include mixed histologies and only a few patients achieve long-term disease-free survival. This retrospective study presents one of the largest prostate-only cohorts, aiming to identify who benefits most from SBRT.

Predictors of long-term disease-free survival with stereotactic body radiotherapy for metachronous oligometastatic prostate cancer

Abstract

Journal

Organization